Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis

Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosisLong-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis, Published online: 16 November 2017; doi:10.1038/leu.2017.330

Source: Leukemia - November 16, 2017 Category: Hematology Authors: A Pardanani J Gotlib A W Roberts M Wadleigh S Sirhan J Kawashima J A Maltzman L Shao V Gupta A Tefferi Source Type: research